- NEUTRAL
Quarterly Revenue Satellos Bioscience Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.
- NEGATIVE
Quarterly Net Profit Satellos Bioscience Inc Jun-2026 Quarterly Net Profit is $-12 Million which is growth of -109.0% YoY.
9.18-0.14(-1.50%)
11,943
XNAS Volume
XNAS 21 Sep, 2026 5:30 PM (EDT)
Satellos Bioscience Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents
Satellos Bioscience Inc quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|---|---|
Operating Rev. | |||||||
Cost Of Rev. | - | - | - | - | - | - | |
Gross Profit | - | - | - | - | - | - | |
| 12.2 | 10 | 7.7 | 6 | 6.4 | 6.5 | ||
Operating Profit | -12.2 | -10 | -7.7 | -6 | -6.4 | -6.5 | |
| 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | ||
Profit Before Tax | -11.7 | -9.7 | -7.2 | -5.8 | -5.6 | -6.1 | |
Tax | 0 | 0 | 0.1 | 0 | 0 | 0.1 | |
| -11.7 | -9.8 | -7.3 | -5.8 | -5.6 | -6.1 | ||
Diluted NI Avail to Com Stockholders Ann. | -11.7 | -9.8 | -7.3 | -5.8 | -5.6 | -6.1 | |
Basic EPS | -0.6 | -0.5 | -0.5 | -0.4 | -0.4 | -0.5 | |
Diluted EPS After ExtraOrdinary | -0.6 | -0.5 | -0.5 | -0.4 | -0.4 | -0.5 | |
Number Of Shares End | 20.8 | 18.4 | 15.5 | 13.9 | 14.3 | 13.8 | |
Net Income Continuing Discontinued Operations | -11.7 | -9.8 | -7.3 | -5.8 | -5.6 | -6.1 | |
Normalized Income | -11.7 | -9.7 | -7.4 | -5.7 | -6 | -6.2 | |
Interest Income | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | |
Interest | - | - | - | - | - | - | |
Net Interest Income | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.4 | |
EBIT | -12.2 | -10 | -7.7 | -6 | -6.4 | -6.5 | |
EBITDA | -12.2 | -10 | -7.7 | -6 | -6.4 | -6.5 | |
Reconciled Cost Of Rev. | - | - | - | - | - | - | |
Reconciled Depr. | |||||||
Profit From Continuing Operations | -11.7 | -9.8 | -7.3 | -5.8 | -5.6 | -6.1 | |
Normalized EBITDA | -12.1 | -9.9 | -7.8 | -5.8 | -6.8 | -6.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Satellos Bioscience Inc competitor comparison and performance snapshot within industry
Satellos Bioscience Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Annual Revenue Satellos Bioscience Inc Annual Revenue is $0 Million which is growth of 0% YoY.
- NEUTRAL
Annual Net Profit Satellos Bioscience Inc Annual Net Profit is $-25 Million which is growth of 0% YoY.
| Indicator | Graph | TTM | Dec '25 |
|---|---|---|---|
Cost Of Rev. Ann. | - | ||
Gross Profit Ann. | - | ||
Operating Exp. Ann. | 35.8 | 26.5 | |
Operating Profit Ann. | -35.8 | -26.5 | |
| 1.6 | 1.4 | ||
Other Exp. Ann. | 0.4 | ||
PBT Ann. | -34.5 | -24.7 | |
Tax Ann. | 0.2 | 0.2 | |
| -34.6 | -24.9 | ||
Diluted NI Avail to Com Stockholders Ann. | -34.6 | -24.9 | |
EPS Ann. | -1.7 | ||
Diluted EPS Ann. | -1.7 | ||
Number Of Shares End | 15.5 | ||
Total Exp. Ann. | 26.5 | ||
Net Income Continuing Discontinued Operations Ann. | -34.6 | -24.9 | |
Normalized Income Ann. | -34.5 | -25.2 | |
Interest Income Ann. | 1.6 | 1.4 | |
Interest Ann. | - | ||
EBITDA Ann. | -35.8 | -26.5 | |
Reconciled Cost Of Rev. Ann. | - | ||
Reconciled Depr. Ann. | 0 | ||
Profit From Continuing Operations Ann. | -34.6 | -24.9 | |
Normalized EBITDA Ann. | -35.6 | -26.9 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Satellos Bioscience Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Total Shareholders Fund Satellos Bioscience Inc Dec-2025 Total Shareholders Fund is $28 Million which is growth of 0% YoY.
- NEUTRAL
Total Assets Satellos Bioscience Inc Dec-2025 Total Assets is $32 Million which is growth of 0% YoY.
| Indicator | Graph | Dec '25 |
|---|---|---|
| 31.9 | ||
| 4.1 | ||
| 27.8 | ||
Total Capitalization Ann. | 27.8 | |
Tangible Assets Ann. | 27.8 | |
Working Capital Ann. | 27.8 | |
Invested Capital Ann. | 27.8 | |
Tangible Book Value Ann. | 27.8 | |
Borrowings Ann. | - | |
Net Debt Ann. | - | |
Share Issued Ann. | 15.5 | |
Number Of Shares End | 15.5 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Satellos Bioscience Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEGATIVE
Book Value Per Share Satellos Bioscience Inc Book Value Per Share is $3 which is growth of -0.4% YoY.
- NEUTRAL
ROE Satellos Bioscience Inc ROE is 0% which is growth of 0% YoY.
| Indicator | Graph | Dec '25 |
|---|---|---|
RoA Ann. % | - | |
ROE Ann. % | - | |
ROIC % | - | |
OPM Ann. % | - | |
Inventory Turnover Ratio Ann. | - | |
Asset Turnover Ann. % | - | |
Working Capital Turnover Ann. | ||
Quick Ratio Ann. | - | |
Current Ratio Ann. | - | |
Interest Coverage Ratio Ann. | - | |
LT Debt To Equity Ann. | - |
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Satellos Bioscience Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history
Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
- NEUTRAL
Cash From Operating Activity Satellos Bioscience Inc Cash From Operating Activity is $-24 Million which is growth of 0% YoY.
- NEUTRAL
Net Cash Flow Satellos Bioscience Inc Net Cash Flow is $-31 Million which is growth of 0% YoY.
| Indicator | Graph | Dec '25 |
|---|---|---|
| -23.6 | ||
| -9.4 | ||
| 2.2 | ||
Cash Plus Cash Eqv. End Of Year Ann. | 9.8 | |
Net Increase In Cash Plus Cash Eqv.s Ann. | -30.8 | |
Cash Plus Cash Eqv. Begin Of Year Ann. | 40.1 | |
Income Tax Paid Supplemental Data Ann. | - | |
Interest Paid Supplemental Data Ann. | - | |
Capex Ann. | -0 | |
Issuance Of Capital Stock Ann. | ||
Issuance Of Debt Ann. | - | |
Repayment Of Debt Ann. | - | |
Repurchase Of Capital Stock Ann. | - | |
Free Cash Flow Ann. | -23.6 |
*All financials are in USD Million and price data in USD
Add metric to table
Search...